| |
Univariate
|
Multivariate
|
|---|
| |
Variables
|
P value
|
P value
|
HR
|
95% CI
|
|---|
|
Categorical Variables
|
CCI
|
0.00001
|
0.00001
|
1.816
|
1.386–2.378
|
|
T-stage
|
0.0004
|
0.0001
|
3.160
|
1.944–5.138
|
|
N-stage
|
0.007
|
0.001
|
1.907
|
1.315–2.767
|
|
Clinical stage
|
0.001
|
0.493
|
0.697
|
0.248–1.96
|
|
PA invasion grade
|
0.028
|
0.0001
|
2.172
|
1.467–3.216
|
|
Continuous Variables
|
KPS
|
0.001
|
0.043
|
0.934
|
0.886–0.936
|
|
GTV
|
0.015
|
0.066
|
0.986
|
0.975–0.997
|
|
CTV
|
0.045
|
0.07
|
1.01
|
1.003–1.017
|
|
PTV
|
0.081
|
0.203
|
0.998
|
0.995–1.001
|
|
PA V10
|
0.099
|
0.698
|
0.275
|
0–16.913
|
|
PA V15
|
0.098
|
0.792
|
0.309
|
0–15.602
|
|
PA V20
|
0.084
|
0.678
|
1.691
|
0–4.357
|
|
PA V25
|
0.094
|
0.468
|
0.022
|
0–6.387
|
|
PA V30
|
0.002
|
0.553
|
8.474
|
0.007–9.855
|
|
PA V35
|
0.001
|
0.111
|
2.367
|
0.271–2.967
|
|
PA V40
|
0.001
|
0.043
|
2.113
|
1.014–4.936
|
|
PA V45
|
0.0004
|
0.0001
|
2.660
|
1.089–5.717
|
|
PA V50
|
0.001
|
0.0001
|
1.203
|
0.062–2.056
|
|
PA V55
|
0.002
|
0.05
|
1.489
|
0.098–2.096
|
|
PA V60
|
0.005
|
0.191
|
0.076
|
0.002–3.621
|
|
PA V65
|
0.027
|
0.149
|
0.069
|
0.002–2.598
|
|
H V30
|
0.062
|
0.148
|
0
|
0–4.075
|
|
H V35
|
0.059
|
0.227
|
1.725
|
0–9.681
|
|
H V40
|
0.035
|
0.755
|
0.001
|
0–5.625
|
|
H V45
|
0.092
|
0.923
|
5.765
|
0–12.916
|
-
CCI Charlson comorbidity index, KPS karnofsky performance status, GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, D95 minimum dose to 95% volume of targets, PA pulmonary artery, PA V5, 10–70: the percentage of PA volume receiving 5,10 to 70Gy, PA
max
the maximum dose to PA, PA
mean
the mean dose to PA, H V5,10-75: the percentage of heart volume receiving 5, 10 to 70Gy, H
max
the maximum dose to heart, H
mean
the mean dose to heart
